FDA still reviewing Cytomedix appeal on foot ulcer gel
April 18 (Reuters) - Cytomedix Inc. (GTF.A) said U.S. regulators are still reviewing the company's appeal regarding marketing clearance for it's gel for healing diabetic foot ulcers called Autogel.
The biotechnology company, in a statement, said it had originally anticipated a decision by this time. It said it hopes a decision would come within the next 60 to 90 days.
In October, the regulators denied Cytomedix's claim that AutoloGel was substantially equivalent to a legally marketed device.
(Reporting by Shikhar Balwani in Bangalore)
((Editing by Bernard Orr; Reuters Messaging: shikhar.balwani.reuters.com@reuters.net; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800)) Keywords: CYTOMEDIX FDA/
(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nWNAS6643
